| Yondelis (trabectedin) / PharmaMar, J&J |
2016-005029-36: Vergleich der Lebensqualität bei Patientinnen mit platinsensitivem wiederkehrenden Eierstock-, Eileiter- und Bachfellkrebs bei der Behandlung mit Trabectedin / PLD oder einer platinbasierten Standardtherapie - eine Kooperation der NOGGO und BNGO |
|
|
| Ongoing | 4 | 206 | Europe | Trabectedin, Pegylated liposomal Doxorubicin, Carboplatin, Gemzitabin, Placlitaxel, L01XA02, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, Yondelis 1 mg powder for solution for infusion, Caelyx, Carboplatin, Gemcitabin, Paclitaxel | NOGGO e.V., PharmaMar, S.A. | Ovarian Cancer, cancer of the ovaries, Diseases [C] - Cancer [C04] | | | | |
COMPASS, NCT03164980: Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer |
|
|
| Completed | 4 | 89 | Europe | Trabectidin (Yondelis) | North Eastern German Society of Gynaecological Oncology, Frankfurter Institut für Klinische Krebsforschung IKF GmbH, PharmaMar | Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma | 08/23 | 08/23 | | |
ACTRN12607000169448: A Phase 3 study comparing the combination of CAELYX and YONDELIS (the study drug) with CAELYX alone in subjects with advanced relapsed ovarian cancer who have previously had platinum based chemotherapy treatment (eg. Carboplatin/Cisplatin) |
|
|
| Recruiting | 3 | 650 | | | Johnson & Johnson Pharmaceutical Research & Development, Johnson & Johnson Pharmaceutical Research & Development | Advanced relapsed Ovarian Cancer - to prolong progression free survival | | | | |
NCT00707109: Trabectedin for Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma |
|
|
| Recruiting | 3 | 1200 | US | trabectedin, Yondelis | University of Medicine and Dentistry New Jersey, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Sarcoma | 12/09 | | | |
2015-004472-30: overall survival of patients with recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype treated with trabectedin compared to a standard treatment valutare la sopravvivenza globale di pazienti con recidiva di tumore ovarico, delle tube di Falloppio o primitivo del peritoneo con mutazione del BRCA o con fenotipo BRCAness, trattati con trabectedina rispetto ad un trattamento standard |
|
|
| Ongoing | 3 | 244 | Europe | Yondelis, ET-743, Powder for solution for injection, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO | FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", Pharma Mar S.A., Fondazione IRCCS Istituto Nazionale Tumori | recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients pazienti con recidiva di tumore ovarico, delle tube di Falloppio o primitivo del peritoneo che presentino una mutazione del BRCA o il fenotipo BRCAness, patients with recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype pazienti con recidiva di tumore ovarico, delle tube di Falloppio o primitivo del peritoneo che risultano BRCA mutate o hanno il fenotipo BRCAness, Diseases [C] - Cancer [C04] | | | | |
2020-005858-21: tTF-NGR Randomized Study - STS tTF-NGR randomisierte Studie - STS |
|
|
| Not yet recruiting | 3 | 126 | Europe | tTF-NGR, Yondelis, ET-743, Solution for infusion in pre-filled syringe, Powder for concentrate for solution for infusion, Yondelis | Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel, ANTUREC Pharmaceuticals GmbH | Patients (18-75 years) with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing 1st line therapy or with contraindications to anthracyclines (CD13 positivity: grade >/= 1+)., Patients with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs., Diseases [C] - Cancer [C04] | | | | |
MANTRA, NCT04979442: Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma |
|
|
| Terminated | 3 | 175 | Europe, Canada, US, RoW | RAIN-32, Milademetan, Trabectedin, Yondelis | Rain Oncology Inc | Dedifferentiated Liposarcoma | 10/23 | 10/23 | | |
2021-001394-23: Clinical study comparing Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma |
|
|
| Not yet recruiting | 3 | 160 | Europe | Milademetan, Trabectedin, DS-3032b, Capsule, Powder for concentrate for solution for infusion | Rain Therapeutics, Inc., Rain Oncology Inc., Rain Therapeuthic Inc, RAIN Therapeutics Inc. | Dedifferentiated liposarcoma, Liposarcoma, Diseases [C] - Cancer [C04] | | | | |
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas |
|
|
| Recruiting | 3 | 333 | US | INT230-6, Eribulin, Trabectedin, Pazopanib | Intensity Therapeutics, Inc., Premier Research Group plc | Sarcoma,Soft Tissue | 12/27 | 12/28 | | |
ISG-STS-1001, NCT01710176: Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy |
|
|
| Active, not recruiting | 3 | 550 | Europe | epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3), gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8), trabectedin 1.3 mg/m2, high-dose ifosfamide 14 g/m2, given in in 14 days, etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3), gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1) | Italian Sarcoma Group, French Sarcoma Group, Grupo Espanol de Investigacion en Sarcomas | Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults | 06/24 | 06/24 | | |
| Recruiting | 3 | 126 | Europe | Trabectedin, Yondelis, tTF-NGR | Universität Münster, Anturec Pharmaceuticals GmbH | Soft Tissue Sarcoma | 12/25 | 12/26 | | |
A092104, NCT05633381: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working |
|
|
| Recruiting | 2/3 | 70 | US | Olaparib, 763113-22-0, Temozolomide, 85622-93-1, Trabectedin, 114899-77-3, Pazopanib, 444731-52-6, 790713-33-6 | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma | 03/30 | 03/30 | | |
NCT05432791: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working |
|
|
| Suspended | 2/3 | 190 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pazopanib, GW786034, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Trabectedin, Ecteinascidin, Ecteinascidin 743, ET 743, ET-743, ET743, Yondelis, Transthoracic Echocardiography, TTE | National Cancer Institute (NCI) | Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma | 03/30 | 03/30 | | |
2ND-STEP, jRCTs031190152: JCOG1802: A randomized phase II trial of 2nd line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib |
|
|
| Active, not recruiting | 2 | 120 | Japan | Yondelis (trabectedin) - Otsuka, PharmaMar, Valeo Pharma, J&J, Halaven (eribulin mesylate) - Eisai, Votrient (pazopanib) - Novartis, BeiGene | Oita University Hospital, National Cancer Center Japan,Japan Agency for Medical Research and Development | Advanced soft tissue sarcoma | | | | |
2006-005009-69: TRABECTEDIN (ET743) IN METASTATIC OR LOCALLY ADVANCED MYXOID/ROUND CELL LIPOSARCOMA PRETREATED WITH CHEMOTHERAPY |
|
|
| Ongoing | 2 | 50 | Europe | Trabectedin, ET743, Powder for infusion* | ISTITUTO NAZIONALE PER LA CURA TUMORI | advanced myxoid/round cell liposarcoma pretreated with anthracycline and ifosfamide | | | | |
2011-001288-32: Preliminary Study to Evaluate the Safety and Tolerability of the combination ot Trabectidin and Indole-3-Carbinol in advanced breast cancer hormonal receptor positive who failed previous chemioterapy treatment Studio iniziale per valutare la sicurezza e la tollerabilita' della combinazione Trabectidina e Indolo-3-Carbinolo nel tumore della mammella con recettori ormonali positivi in fase avanzata,gia' trattato senza beneficio con terapie precedenti |
|
|
| Ongoing | 2 | 15 | Europe | Concentrate for solution for injection, YONDELIS*EV 1FL POLV 1MG | FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE, Pharmamar | Refractory ER-positive metastatic breast cancer Carcinoma mammario metastatico e refrattario ER-positivo, Hormonal receptor positive advanced brast cancer brast cancer who failed previous treatment Tumore mammario con recettori ormonali positivi in fase avanzata che non ha beneficiato di terapie precedenti, Diseases [C] - Cancer [C04] | | | | |
2007-006681-15: Ensayo Clínico de Fase II de Trabectedina tras Progresión a Terapia Antitumoralbasada en Platino en Pacientes con Cáncer No Microcítico de Pulmón (CNMP)Avanzado con Sobreexpresión de XPG y/o ERCC1, y Subexpresión de BRCA1 |
|
|
| Ongoing | 2 | 60 | Europe | Yondelis®, ET-743, Yondelis® 0.25 mg and Yondelis® 1 mg, Yondelis® 0.25 mg and Yondelis® 1 mg | Pharma Mar, S.A. | Cáncer no microcítico de pulmón (CNMP) avanzado | | | | |
2011-000137-36: USE OF TRABECTEDIN IN PATIENTS WITH RELAPSED/PROGRESSION OF EPITHELIAL CARCINOMA OVARY |
|
|
| Ongoing | 2 | 50 | Europe | YONDELIS, CAELYX, YONDELIS, CAELYX | UNIVERSITA, CAMPUS BIOMEDICO | epithelial ovarian carcinoma | | | | |
2017-000987-14: Maintenance therapy with Trabectedin after combination therapy Liposomal Doxorubicin plus Trabectedin vs Liposomal Doxorubicin plus Trabectedin in patients affected by relapsed ovarian cancer. Studio di fase II:Terapia di mantenimento con Trabectedina dopo terapia di combinazione con Doxorubicina Liposomiale e Trabectedina in pazienti affetti da carcinoma ovarico. |
|
|
| Ongoing | 2 | 130 | Europe | Trabectedina, [Trabectedina], Powder for solution for infusion, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO | AZIENDA OSPEDALIERA PER L'EMERGENZA CANNIZZARO, Pharma Mar SA | Ovarian cancer Carcinoma ovarico, Ovarian tumour Tumore ovarico, Diseases [C] - Cancer [C04] | | | | |
2017-001755-31: Study to Compare a Treatment with Trabectedin and Olaparib to Physician’s Choice in Subjects with Previously Treated Solid Tumors Having a Special lack of Cellular Repair Mechanism Studie zu einer Behandlung mit Trabectedin und Olaparib im Vergleich zu Standardbehandlung nach ärztlichem Ermessen bei Patienten mit soliden Tumoren, die eine gestörte Zellreparatur haben. |
|
|
| Not yet recruiting | 2 | 108 | Europe | Trabectedin, Olaparib, ET-743, Powder for concentrate for solution for infusion, Film-coated tablet, Yondelis | Ruprecht-Karls-Universität Heidelberg, Medical Faculty, DKFZ Heidelberg, AstraZeneca GmbH, Pharma Mar S.A. | Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies Patienten mit lokal fortgeschrittenen bzw. metastasierten soliden Organtumoren bei molekulargenetisch nachgewiesenen Störungen im DNA-Reparaturweg, Previously Treated Advanced Tumors Fortgeschrittene Krebserkrankung, die bereits behandelt wurde, Diseases [C] - Cancer [C04] | | | | |
2018-000230-35: combination of trabectedin and olaparib in ovarian cancer, fallopian tubes and primary of peritoneum already resistant to standard platinum drugs studio di trabectedina e olaparib nei tumori dell'ovaio delle tube di falloppio e dei primitivi del peritoneo in stadio avanzato in cui i trattamenti standard a base di platino non hanno più effetto. |
|
|
| Ongoing | 2 | 66 | Europe | yondelis, olaparib, [ET-743], [AZD-2281], Powder for solution for injection, Tablet, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO | FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS, AstraZeneca | platinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneum Carcinoma Ovarico, delle tube di Falloppio e dei primitivi del peritoneo platino-resistente, ovarian cancer, fallopian tubes cancer or primary of peritoneum no longer sensitive to standard platinum drugs tumore delle ovaie, delle tube e dei primtivi del peritoneo non più trattabile con i trattamenti standard a base di platino, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2015-005153-12: Phase II trial on trabectedin in the treatment of advanced uterine and ovarian carcinosarcoma (Cs) Studio di Fase II con Trabectedina nel trattamento delcarcinosarcoma ovarico o uterino in stadio avanzato |
|
|
| Ongoing | 2 | 43 | Europe | YONDELIS, [YONDELIS], Powder for solution for infusion, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO | FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Pharma Mar Srl Italy | advanced ovarian and uterine carcinosarcoma carcinosarcoma ovarico o uterino in stadio avanzato, advanced ovarian and uterine carcinosarcoma carcinosarcoma ovarico o uterino in stadio avanzato, Diseases [C] - Cancer [C04] | | | | |
2017-004690-14: RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36) RECHALLENGE CON DOXORUBICINA LIPOSOMALE PEGILATA IN AGGIUNTA ALLA TRABECTEDINA NELLA RECIDIVA DI TUMORE OVARICO: STUDIO PROSPETTICO MULTICENTRICO (REPRAB study – MITO 36) |
|
|
| Not yet recruiting | 2 | 64 | Europe | Trabectedin, Caelyx, [0], Concentrate for solution for injection/infusion, YONDELIS - 025 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO- FLACONCINO (VETRO) 1 FLACONCINO, CAELYX - 2 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO 10 ML USO EV | FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Pharma Mar S.A. | Ovarian cancer Carcinoma ovarico, Ovarian cancer Tumore dell'ovaio, Diseases [C] - Cancer [C04] | | | | |
2019-003733-41: Study on advanced rearranged Mesenchymal chondrosarcoma Studio per il trattamento dia condrosarcoma mesenchimale (HEY1-NOCOA2 riarrangiato) scheletrico ed extra-scheletrico con malattia avanzata |
|
|
| Not yet recruiting | 2 | 20 | Europe | trabectedina, [trabectedina], Powder for infusion, Yondelis | ITALIAN SARCOMA GROUP, Pharma Mar S.A | Patients with advanced, histological and molecularly (presence of the HEY1-NCOA2 fusion) centrally confirmed diagnosis of MCS, with an evidence of RECIST progression within the 6 months prior to starting the study treatment and pre-treated with anthracycline-based chemotherapy Pazienti giovani adulti o adulti affetti da condrosarcoma mesenchimale HEY1-NCOA2 riarrangiato a partenza scheletrica o extra-scheletrica avanzato e in progressione, Advanced Mesenchimal Condrosarcoma Condrosarcoma mesenchimale in fase avanzata, Diseases [C] - Cancer [C04] | | | | |
2020-005626-29: A PHASE II CLINICAL STUDY, ON TRABECTEDIN IN COMBINATION WITH PPARg AGONIST PIOGLITAZONE IN PATIENTS WITH ROUND CELL MYXOID LIPOSARCOMAS OR DEDIFFERENTIATED G1 OR G2 LIPOSARCOMAS WITH STABLE DISEASE IN TREATMENT WITH TRABECTEDIN ALONE. STUDIO CLINICO DI FASE II, VOLTO A VALUTARE L'ASSOCIAZIONE DEL FARMACO TRABECTEDINA E DEL FARMACO PIOGLITAZONE PPARPg AGONISTA, IN PAZIENTI CON LIPOSARCOMA DI TIPO MIXOIDE/ A CELLULE ROTONDE O LIPOSARCOMA DEDIFFERENZIATO G1 E G2, CON MALATTIA STABILE E IN TRATTAMENTO CON IL FARMACO TRABECTEDINA. |
|
|
| Not yet recruiting | 2 | 10 | Europe | Pioglitazone, Trabectedina, [Pioglitazone], [Trabectedina], Tablet, Powder for concentrate for solution for infusion, Pioglitazone, Yondelis | IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, AIRC (bandi per la ricerca indipendente) | Patients with myxoid/round cell liposarcoma treated with at least 4 cycle of T alone with a stable disease at the last tumor evaluation Pazienti con diagnosi di liposarcoma mixoide/a cellule rotonde trattati per almeno 4 cicli con trabectedina da sola e con malattia stabile in base all’ultima valutazione di malattia., Patients who have been diagnosed with round cell myxoid liposarcoma and who have been treated with only trabectedin and who according to the latest assessment have stable disease. Pazienti con diagnosi di liposarcoma di tipo mixoide/ a cellule rotonde che sono stati trattati negli ultimi 4 cicli con solo il farmaco trabectedina e con malattia stabile all'ultima valutazione., Diseases [C] - Cancer [C04] | | | | |
2020-000741-13: Trial assessing the activity of TrabectedIn vs gemCitabine in patients with advanced LEiomyosarcoma Studio sull’attività della Trabectedina vs Gemcitabina in pazienti con leiomiosarcoma avanzato pretrattati c |
|
|
| Not yet recruiting | 2 | 100 | Europe | Trabectedina, Gemcitabina, [trabectedina], [Gemcitabina], Powder for infusion, Concentrate for solution for infusion, Yondelis, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 2 ML | ITALIAN SARCOMA GROUP, Pharmamar | metastatic or locally advanced Leiomyosarcoma pretreated with conventional chemotherapy leiomiosarcoma metastatico o localmente avanzato pretrattati con chemioterapia convenzionale, advanced Leiomyosarcoma leiomiosarcoma avanzato, Diseases [C] - Cancer [C04] | | | | |
2017-001083-38: Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas |
|
|
| Not yet recruiting | 2 | 92 | Europe | Nivolumab, Trabectedin, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Opdivo®, Yondelis | Universitätsmedizin Greifswald, Bristol-Myers Squibb GmbH und Co. KG, Pharma Mar, S.A. | metastatic or inoperable soft tissue sarcoma metastasiertes oder inoperables Weichteilsarkom, metastatic or inoperable soft tissue sarcoma metastasiertes oder inoperables Weichteilsarkom, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 2 | 64 | Europe | PLD and Trabectedin rechallenge | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Relapsed Ovarian Cancer | 04/22 | 04/22 | | |
NCT04076579: Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma |
|
|
| Active, not recruiting | 2 | 29 | US | Olaparib, Trabectedin | University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC, AstraZeneca | Sarcoma, Sarcoma Metastatic | 01/23 | 01/25 | | |
| Active, not recruiting | 2 | 120 | Europe | Trabectedin, Yondelis, DNA double-strand breaks | Ludwig-Maximilians - University of Munich | Sarcoma | 08/23 | 08/23 | | |
| Completed | 2 | 102 | Europe | Olaparib, Physician's choice, Trabectedin | National Center for Tumor Diseases, Heidelberg, AstraZeneca, PharmaMar, German Cancer Research Center | Cancers With DNA Repair-Deficiency | 12/23 | 12/23 | | |
| Recruiting | 2 | 40 | US | Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], TVEC, Imlygic, Nivolumab IV Soln 100 MG/10ML, Opdivo, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution, Yondelis | Sarcoma Oncology Research Center, LLC | Sarcoma | 12/24 | 03/25 | | |
| Active, not recruiting | 2 | 23 | Europe | Trabectedin, Adriamycin, Dacarbazine | Italian Sarcoma Group | Solitary Fibrous Tumors | 12/24 | 12/24 | | |
TRABEPIO, NCT04794127: Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. |
|
|
| Recruiting | 2 | 10 | Europe | Trabectedin, Trabectedine, Pioglitazone Oral Product, Pioglitazone | Mario Negri Institute for Pharmacological Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Humanitas Hospital, Italy | Liposarcoma, Myxoid, Liposarcoma, Dedifferentiated, Liposarcoma, Round Cell | 12/24 | 02/25 | | |
| Recruiting | 2 | 100 | Europe | Trabectedin, Trabectedin arm, Gemcitabine, Gemcitabine arm, No Intervention: Observational Cohort | Italian Sarcoma Group, PharmaMar | Leiomyosarcoma of Ovary, Soft Tissue Sarcoma | 06/24 | 09/24 | | |
SYNERGIAS, NCT05131386: Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas |
|
|
| Recruiting | 2 | 85 | Europe | Trabectedin, Yondelis | Grupo Espanol de Investigacion en Sarcomas | Soft Tissue Sarcoma, Bone Tumors, Small Round-cell Sarcomas | 07/24 | 07/24 | | |
| Recruiting | 2 | 16 | Europe | Trabectedin | Italian Sarcoma Group, PharmaMar | Mesenchymal Chondrosarcoma | 09/24 | 12/24 | | |
| Recruiting | 2 | 80 | US | Trabectedin, Gemcitabine, Dacarbazine | Sarcoma Oncology Research Center, LLC | Leiomyosarcoma | 09/24 | 12/24 | | |
L-UteCIN, NCT06524583: Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour |
|
|
| Not yet recruiting | 2 | 198 | Europe | Doxorubicin, Trabectedin, Yondelis | UNICANCER, PharmaMar, Ligue contre le cancer, France, National Research Agency, France, University Hospital, Marseille, Institut Claudius Regaud, Institut Bergonié, Oncopole | Leiomyosarcoma Uterus | 12/29 | 12/30 | | |
| Active, not recruiting | 2 | 126 | Europe | Standard arm: Trabectedin in monotherapy, Trabectedin arm, Experimental arm: Trabectedin + Olaparib, Trabectedin+ Olaparib arm | Italian Sarcoma Group, PharmaMar, AstraZeneca | Advanced Soft Tissue Sarcoma | 02/25 | 02/25 | | |
2014-001549-26: Trial that evaluates the combination treatment of Trabectedin and Radiotherapy in Soft Tissue Sarcoma patients. Ensayo clínico que evalúa la combinación de Trabectedina y Radioterapia para el tratamiento de pacientes con sarcoma de tejidos blandas. |
|
|
| Ongoing | 1/2 | 148 | Europe | trabectedina, [trabectedina], Powder for concentrate for solution for infusion, YONDELIS 1 mg powder for concentrate for solution for infusion | GEIS, GRUPO ESPAñOL DE INVESTIGACIóN EN SARCOMAS, PharmaMar, Pharmamar | Soft Tissue Sarcoma Sarcoma de tejidos blandos, Soft Tissue Sarcoma Sarcoma de tejidos blandos, Diseases [C] - Cancer [C04] | | | | |
2015-002760-16: Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly trabectedin combined with Metronomic Cyclophosphamide in Patients with Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II study from the French Sarcoma Group. |
|
|
| Ongoing | 1/2 | 71 | Europe | Coated tablet, Powder for concentrate for solution for infusion, ENDOXAN, YONDELIS | INSTITUT BERGONIE, Pharma Mar S.A., Institut Bergonié | Adult patients with unresectable locally advanced or metastatic soft-tissue sarcoma., Adult patients with unresectable locally advanced or metastatic soft-tissue sarcoma., Diseases [C] - Cancer [C04] | | | | |
2009-011041-12: Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis®) en association avec l’oxaliplatine chez des patientes atteintes d’un cancer de l’ovaire avancé prétraité. |
|
|
| Ongoing | 1/2 | 64 | Europe | Yondelis, Oxaliplatin, ET-743, Yondelis 0.25 mg and 1.0 mg, Yondelis 0.25 mg and 1.0 mg | Pharma Mar S.A. | Pretreated Advanced Ovarian Cancer | | | | |
TARMIC, NCT02805725: Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide |
|
|
| Completed | 1/2 | 50 | Europe | Phase 1: Trabectedin, Phase 2: Trabectedin, Phase 1: Cyclophosphamide, Phase 2: Cyclophosphamide | Institut Bergonié, PharmaMar | Soft-tissue Sarcomas | 04/20 | 12/21 | | |
SAINT, NCT03138161: Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma |
|
|
| Recruiting | 1/2 | 45 | US | Trabectedin, Yondelis, Ipilimumab, Yervoy, Nivolumab, Opdivo | Sarcoma Oncology Research Center, LLC, Bristol-Myers Squibb | Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma | 12/24 | 03/25 | | |
SARC037, NCT04067115: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients |
|
|
| Active, not recruiting | 1/2 | 48 | US | Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy, 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging, 18F-FLT Imaging | Sarcoma Alliance for Research through Collaboration, Janssen Scientific Affairs, LLC, National Institutes of Health (NIH), National Cancer Institute (NCI) | Ewing Sarcoma | 06/24 | 06/24 | | |
| Recruiting | 1/2 | 199 | Europe | Trabectedin, Yondelis, Radiotherapy | Grupo Espanol de Investigacion en Sarcomas, Centre Leon Berard, Italian Sarcoma Group | Liposarcoma, Myxoid, Sarcoma, Soft Tissue, Leiomyosarcoma, Liposarcoma, Pleomorphic Liposarcoma | 06/28 | 06/28 | | |
TRAMUNE, NCT03085225: Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. |
|
|
| Completed | 1 | 40 | Europe | Combination of trabectedin with durvalumab | Institut Bergonié, AstraZeneca, PharmaMar | Ovarian Carcinoma, Soft Tissue Sarcoma | 11/20 | 01/22 | | |
|
OLATRASTS, NCT03985722: Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients |
|
|
| Active, not recruiting | 1 | 28 | Europe | Olaratumab and Trabectedin, Lartruvo and Yondelis | Grupo Espanol de Investigacion en Sarcomas | Sarcoma, Soft Tissue | 02/21 | 05/24 | | |
NCT01427582: YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access |
|
|
| No Longer Available | N/A | | US | Trabectedin, YONDELIS | University of Texas Southwestern Medical Center, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Soft Tissue Sarcoma | | | | |
NCT00210665: A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment |
|
|
| No Longer Available | N/A | | US, Canada, RoW | Trabectedin | Janssen Research & Development, LLC | Sarcoma | | | | |
GEICO 105-O, NCT05868889: Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD |
|
|
| Completed | N/A | 43 | Europe | Trabectedin and PLD | Grupo Español de Investigación en Cáncer de Ovario | Ovarian Cancer | 06/22 | 06/22 | | |
PIPER, NCT04008238: Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients |
|
|
| Recruiting | N/A | 200 | Europe | Trabectedin | Institut Bergonié | Soft Tissue Sarcoma Adult, Undifferentiated Pleomorphic Sarcoma, Epithelioid Sarcoma, Solitary Fibrous Tumors, Hemangioendothelioma, Desmoplastic Round Cell Tumor, Synovial Sarcoma | 01/24 | 01/25 | | |
PROTraSarc, NCT06050434: Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients |
|
|
| Recruiting | N/A | 100 | Europe | | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, PharmaMar | Soft Tissue Sarcoma | 05/25 | 12/25 | | |